RESUMEN
Over the past decade, there have been major advances in our understanding of the role of glutamate and N-methyl-d-aspartate (NMDA) receptors in several disorders of the central nervous system, including stroke, Parkinson's disease, Huntington's disease and chronic/neuropathic pain. In particular, NR2B subunit-containing NMDA receptors have been the focus of intense study from both a physiological and a pharmacological perspective, with several pharmaceutical companies developing NR2B subtype-selective antagonists for several glutamate-mediated diseases. Recent studies have shown the importance of NR2B subunits for NMDA receptor localization and endocytosis, and have suggested a role for NR2B-containing NMDA receptors in the underlying pathophysiology of neurodegenerative disorders such as Alzheimer's and Huntington's diseases. Anatomical, biochemical and pharmacological studies over the past five years have greatly added to our understanding of the role of NR2B subunit-containing NMDA receptors in chronic and neuropathic pain states, and have shown that NR2B-mediated analgesic effects might be supra- rather than intra-spinally mediated, and that phosphorylation of the NR2B subunit could be responsible for the initiation and maintenance of the central sensitization seen in neuropathic pain states. These data will hopefully provide the impetus for development of novel compounds that use multiple approaches to modulate the activity of NR2B subunit-containing NMDA receptors, thus bringing to fruition the promise of therapeutic efficacy utilizing this approach.
Asunto(s)
Isquemia Encefálica/tratamiento farmacológico , Antagonistas de Aminoácidos Excitadores/uso terapéutico , Enfermedad de Huntington/tratamiento farmacológico , Dolor/tratamiento farmacológico , Receptores de N-Metil-D-Aspartato/antagonistas & inhibidores , Animales , Isquemia Encefálica/metabolismo , Ensayos Clínicos como Asunto , Modelos Animales de Enfermedad , Antagonistas de Aminoácidos Excitadores/farmacología , Ácido Glutámico/metabolismo , Humanos , Enfermedad de Huntington/metabolismo , Dolor/metabolismo , Fenoles/farmacología , Fenoles/uso terapéutico , Piperidinas/farmacología , Piperidinas/uso terapéutico , Conformación Proteica , Receptores de N-Metil-D-Aspartato/metabolismoRESUMEN
The melanocortin-4 receptor (MC4R) plays an important role in the regulation of energy homeostasis. Recent studies have shown that blockade of the MC4R reverses tumor-induced weight loss in mice. Herein, we describe the synthesis and identification of potent and selective non-peptide antagonists of the human MC4R from a series of 2-ethoxycarbonylcyclohexyl-piperazines. Compound 12i was found to possess low nanomolar affinity for the MC4R, and exhibit oral bioavailability in rats. More importantly, when administered orally to mice (10 mg/kg), it led to statistically significant increases in food intake over a 24-h period.
Asunto(s)
Piperazinas/síntesis química , Receptor de Melanocortina Tipo 4/antagonistas & inhibidores , Administración Oral , Animales , Disponibilidad Biológica , Caquexia/tratamiento farmacológico , Ingestión de Alimentos/efectos de los fármacos , Humanos , Piperazinas/farmacocinética , Piperazinas/farmacología , Unión Proteica , Ratas , Relación Estructura-ActividadRESUMEN
Derivatives of 1-(4-amino-phenyl)-pyrrolidin-3-yl-amine and 6-(3-amino-pyrrolidin-1-yl)-pyridin-3-yl-amine were identified as potent and functionally active MCH-R1 antagonists. One compound with Ki = 2.3 nM demonstrated good oral bioavailability (32%) and in vivo efficacy in rats.
Asunto(s)
Piridinas/farmacología , Pirrolidinas/farmacología , Receptores de Somatostatina/antagonistas & inhibidores , Administración Oral , Animales , Disponibilidad Biológica , Peso Corporal , Evaluación Preclínica de Medicamentos , Humanos , Masculino , Modelos Animales , Estructura Molecular , Piridinas/química , Piridinas/farmacocinética , Pirrolidinas/química , Pirrolidinas/farmacocinética , Ratas , Ratas Wistar , Receptores de Somatostatina/metabolismo , Relación Estructura-ActividadRESUMEN
Indiplon (NBI 34060; N-methyl-N-[3-[3-(2-thienylcarbonyl)-pyrazolo[1,5-alpha]pyrimidin-7-yl]phenyl]acetamide), a novel pyrazolopyrimidine and high-affinity allosteric potentiator of GABA(A) receptor function, was profiled for its effects in rodents after oral administration. In mice, indiplon inhibited locomotor activity (ED(50) = 2.7 mg/kg p.o.) at doses lower than the nonbenzodiazepine hypnotics zolpidem (ED(50) = 6.1 mg/kg p.o.) and zaleplon (ED(50) = 24.6 mg/kg p.o.), a sedative effect that was reversed by the benzodiazepine site antagonist flumazenil. Indiplon inhibited retention in the mouse passive avoidance paradigm over a dose range and with a temporal profile that coincided with its sedative activity. Indiplon, zolpidem, and zaleplon were equally effective in inhibiting locomotor activity in the rat and produced dose-related deficits on the rotarod. In a rat vigilance paradigm, indiplon, zolpidem, and zaleplon produced performance deficits over a dose range consistent with their sedative effects, although indiplon alone showed no significant increase in response latency. Indiplon produced a small deficit in the delayed nonmatch to sample paradigm at a dose where sedative effects became apparent. Indiplon was active in the rat Vogel test of anxiety, but it showed only a sedative profile in the mouse open field test. The pharmacokinetic profile of indiplon in both rat and mouse was consistent with its pharmacodynamic properties and indicated a rapid T(max), short t(1/2), and excellent blood-brain barrier penetration. Therefore, indiplon has the in vivo profile of an efficacious sedative-hypnotic, in agreement with its in vitro receptor pharmacology as a high-affinity allosteric potentiator of GABA(A) receptor function, with selectivity for alpha1 subunit-containing GABA(A) receptors.